International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-4 doi: 10.5281/zenodo.8201799
Original Article
Study of Electrocardiographic (ECG) Changes in COPD (Chronic Obstructive Pulmonary Disease) Patients and Assessing the Severity of the Disease
 ,
Published
Aug. 1, 2023
Abstract

Introduction: COPD is a common, preventable, and treatable chronic lung disease Characterized by airflow limitation that is not fully reversible causing breathing-related problems. Cardiovascular disease accounts for significant morbidity and mortality in COPD. Severe COPD can cause heart failure or long-term cardiac complications. Electrocardiography provides a rapid, non-invasive method to evaluate cardiac functions.

Aims and Objective: To study the ECG changes in COPD patients and assess these ECG changes with severity of the disease.

Materials and Methods: It is a cross sectional study from September 2022 to November 2022 done in Department of General Medicine, KR hospital, MMCRI, Mysore. Study conducted on 100 COPD patients confirmed by PFT. After taking institutional ethical clearance 12 lead ECG is performed and assessed with severity categorized by GOLD criteria into mild, moderate, severe, and very severe.

Statistical Analysis: Data obtained from the study will be entered in excel sheets and it will be double checked. Data analysed using SPSS software version 22.0 and it will be presented as descriptive statistics in form of frequency table and figures. Result will be expressed. Correlation of parameters is done by Pearson’s correlation formula. A p value of <0.05 is considered statistically significant.

Results and Conclusion: In our study 2 cases in mild, 48 cases in moderate, 39 cases in severe and 11 cases in very severe group.68% had RAD,60% had sinus tachycardia,63% had p pulmonale,44% has R/S(V1>1),36% had R/S(v6<1),33% had RBBB,17% had MAT,11% had lead 1 sign. Long smoking duration had very severe PFT changes and more prevalent ECG changes were in severe group. ECG can be used as a screening test in assessing the severity of the disease and further preventing morbidity.

Recommended Articles
Loading Image...
Volume-4, Issue-4
Citations
526 Views
332 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved